

Supplementary Figures




Figure S1. Stability of $[^{89}\text{Zr}]\text{Zr-DFO-anti-TRA scFv-Fc}$ from post-purification (Baseline) through 96 h of incubation in saline at 37 °C.




Figure S2. Tissue distribution of $[^{89}\text{Zr}]\text{Zr-DFO-anti-TRA}$ in BxPC-3-bearing athymic nude mice.




Figure S3. Immunofluorescence detection of TRA-1-60 (red) expression in (A) BxPC3 and (B) AsPC-1 with DAPI (blue) as a nuclear counterstain.




Figure S4. (A) AsPC-1 tumor volume trajectories for each treatment group over time. Individual tumor volume trajectories are shown as semi-transparent lines, with solid lines representing model-fitted mean growth curves for each treatment group. **(B)** Kaplan-Meier curves for tumor latency across treatment groups. Tumor latency, defined as the time until tumor volume reached 600 mm³.